To evaluate the steady-state pharmacokinetics of prednisone and its metabolite prednisolone in pregnant and lactating female subjects, 19 subjects received prednisone (4-40 mg/day orally) in early (n = 3), mid (n = 9), and late (n = 13) pregnancy as well as postpartum with (n = 2) and without (n = 5) lactation. Serial blood and urine samples were collected over 1 dosing interval. Prednisone and its metabolite, prednisolone, steadystate noncompartmental pharmacokinetic parameters were estimated. During pregnancy, prednisone apparent oral clearance increased with dose (35.1 ± 11.4 L/h with 5 mg, 52.6 ± 5.2 L/h with 10 mg, and 64.3 ± 6.9 L/h with 20 mg, P = .001). Similarly, unbound prednisone apparent oral clearance increased with dose. In addition, prednisolone renal clearance increased with dose (0.3 ± 0.3 L/h with 5 mg, 0.5 ± 0.4 L/h with 10 mg, and 1.3 ± 1.1 L/h with 20 mg, P = .002). Higher prednisone (r = 0.57, P ࣘ .05) and prednisolone (r = 0.75, P ࣘ .05) concentrations led to a higher percentage of unbound drug. Breast-milk/plasma area under the concentration-time curve ratios were 0.5-0.6 for prednisone and 0.02-0.03 for prednisolone. Relative infant doses were 0.35% to 0.53% and 0.09% to 0.18%, for prednisone and prednisolone, respectively. Prednisone and prednisolone exhibit dose-and concentration-dependent pharmacokinetics during pregnancy, and infant exposure to these agents via breast milk is minimal.
binding globulin (CBG or transcortin) and albumin in plasma. CBG concentrations increase and albumin concentrations decrease during gestation. 6 The effects of pregnancy on prednisone and prednisolone PK and plasma protein binding have not been evaluated. Therefore, the objective of this study was to evaluate the PK of prednisone and its active metabolite, prednisolone, during pregnancy and postpartum.
Methods

Subjects
The study protocol was approved by the institutional review boards at the University of Washington, University of Pittsburgh, Georgetown University, and University of Texas Medical Branch in Galveston. All subjects were enrolled after obtaining written informed consent. We examined steady-state PK of orally administered prednisone in the plasma of 19 female subjects, 16 to 41 years of age with hematocrits ࣙ28% and receiving prednisone for therapeutic reasons. Blood and urine samples were collected during early (10-14 weeks gestation), mid-(22-26 weeks gestation), and late pregnancy (34-38 weeks gestation), as well as ࣙ12 weeks postpartum with and without lactation, depending on the subject's time of enrollment and availability.
Maternal Dosing Regimen
Prednisone was dosed according to clinical need, without regard to the study. Total daily doses ranged from 4 mg to 40 mg, given once or twice daily. Dosing administration times were recorded for the 3 days before study visits, and pill counts were conducted to assess adherence. Subjects fasted (except for clear liquids) for 5 hours before observed prednisone administration until 1 hour after dosing on each study day. Subjects avoided caffeine, grapefruit-containing foods and beverages, and alcohol for 24 hours before each study day and throughout the sampling period.
Sample Collection
Serial blood samples were collected from an indwelling venous catheter predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours following prednisone dosing, truncated to the subject's dosing interval. Blood was collected in green top tubes containing sodium heparin as an anticoagulant. Samples were processed and plasma frozen immediately. Urine was collected over 1 dosing interval for evaluation of prednisone and prednisolone urinary excretion as well as creatinine clearance. Venous (n = 13) and arterial (n = 6) umbilical cord plasma samples were collected at the time of delivery. Intrapartum maternal blood samples were collected immediately after delivery. Breast milk was collected from 2 subjects. Both breasts were completely emptied of milk every 2-3 hours using a Medela Classic R double electric breast pump (Medela Inc, McHenry, Illinois) over 1 dosing interval. Breastfeeding was not allowed during the postpartum study days. After each breast-milk collection, volume measurement, and sample collection, remaining breast milk was returned to the mother for infant feeding. Samples were stored at -80°C until analysis.
Prednisone and Prednisolone Concentrations. Plasma, urine, and breast-milk concentrations of prednisone and prednisolone were determined using reverse-phase high-performance liquid chromatography (HPLC) with mass spectrometry (MS) detection. Assay conditions are reported in Supplemental Table S1 . An Agilent 1200 HPLC and 1956B mass spectrometer (Agilent Technologies, Santa Clara, California) were used for the analysis of prednisone and prednisolone. A Restek Allure Biphenyl 2.1 mm × 100 mm, 3-μm (Restek Corp, Bellefonte, Pennsylvania) column was used for plasma and breast-milk samples. An Agilent Zorbax SB-phenyl 2.1 mm × 150 mm, 5-μm column was used for urine samples. Monitored ions included m/z 393 for M+Cl for prednisone, m/z 395 for M+Cl for prednisolone, and m/z 401 for M+Cl for d6-prednisolone (Supplemental Figure S1 for plasma and Supplemental Figure S2 for urine).
Plasma and breast-milk samples (250 μL) were combined with the internal standard (40 ng d 6 -prednisolone), methanol (100 μL), and acetonitrile (1000 μL) to precipitate the proteins. After centrifugation (20,800g, 10 minutes), the supernatant was evaporated to dryness and reconstituted in 100 μL of mobile phase. The reconstituted samples were centrifuged again, and 5 μL was injected onto the HPLC column. The dynamic range was 4 to 800 ng/mL. The interday variability was less than 6% for both compounds. Urine samples (50 μL) were combined with mobile phase (100 μL) containing internal standard (40 ng), and 2 μL was injected onto the HPLC column. The dynamic range was 20 to 4000 ng/mL. The interday variability was less than 8% for both compounds.
Unbound Prednisone and Prednisolone
The unbound fraction was concentration dependent, so protein binding was determined for each plasma and breast-milk sample. The unbound fractions were determined by equilibrium dialysis using Pierce rapid equilibrium dialysis devices (Thermo Fisher, Waltham, Massachusetts). The sample chamber contained 400 μL of plasma or breast milk, and the buffer contained 600 μL buffer (0.1 mol/L sodium phosphate, 0.15 mol/L sodium chloride, pH 7.2). Incubation was 4 hours at 100 rpm and 37°C. After incubation, 300-μL aliquots of each side were extracted (15 minutes) using 3 mL ethyl acetate-containing internal standard (40 ng d 6 -prednisolone). Steroid-free plasma or buffer was added to normalize contents. The organic layer was evaporated to dryness and reconstituted in 75 μL (1:1 5 mmol/L ammonium formate:methanol). After centrifugation, 2 μL was injected onto the HPLC column (Phenomenex Luna C-18, 150 mm × 3 mm, 3 μm, Phenomenex, Torrance, California). The dynamic range was 0.2 to 100 ng/mL. The interday variability was less than 5% for both compounds. The HPLC-MS method used for determining the concentration of prednisone and prednisolone in biofluids was adapted for the analysis of the unbound fractions, and the conditions can be found in Supplemental Table S1 and the gradient in Supplemental Table S2 . Monitored ions were m/z 359.1 for prednisone, m/z 361 for prednisolone, and 367 for d 6 -prednisolone (Supplemental Figure S3) . The percentage of unbound drug was determined by the concentration in the buffer chamber divided by the concentration in the plasma chamber × 100.
Pharmacokinetic Analyses
Prednisone steady-state noncompartmental PK parameters were estimated utilizing Phoenix WinNonlin software (Certara, LP, Princeton, New Jersey) as previously described. 7 Total plasma area under the concentration-time curve (AUC) over 1 dosing interval was estimated utilizing linear trapezoidal rule. Prednisone apparent oral clearance (CL/F) was estimated as CL/F = dose/AUC. Because separate administration of prednisolone was not performed, prednisolone oral clearance was estimated with reference to the prednisone dose as described by Rose et al 5 and estimated by prednisolone CL/F = prednisone dose/prednisolone AUC. Dose was not adjusted for molecular weight differences given the very small difference and to be consistent with previously published work. 5 Apparent oral volume of distribution (Vβ/F) was estimated as Vβ/F = (CL/F)/k, in which k was the terminal elimination rate constant determined by log-linear regression. The prednisolone/prednisone metabolic ratio (MR) was estimated as AUC prednisolone /AUC prednisone for plasma and Ae prednisolone /Ae prednisone for urine in which Ae was the amount of unchanged prednisone or prednisolone excreted in the urine over 1 dosing interval. Prednisone and prednisolone renal clearance was calculated by CL R, prednisone = Ae prednisone /AUC prednisone and CL R, prednisolone = Ae prednisolone /AUC prednisolone , respectively. The percentage of dose excreted in urine was calculated by (Ae prednisone /prednisone dose) × 100 and (Ae prednisolone /prednisone dose) × 100 for prednisone and prednisolone, respectively. 5 Actual body weights were used for weight-adjusted parameters. When concentrations fell below the lower limit of quantitation before the end of the dosing interval, the concentration at the end of the dosing interval (C end ) was determined by extrapolating from the last measured concentration (C last ) to the end of the dosing interval by C end = C last × e -kt in which k was the elimination rate constant and t was the time interval between C last and C end .
The amount of prednisone and prednisolone excreted in the breast milk over the dosing interval was determined by summing the amount excreted during each breast-milk collection (breast-milk volume × concentration). The prednisone or prednisolone breast milk/plasma AUC ratio was determined by (breastmilk AUC)/(maternal plasma AUC). The percentage of maternal prednisone dose excreted unchanged in breast milk was determined by (amount of prednisone excreted in the breast milk over 1 dosing interval/maternal prednisone dose) × 100. The percentage of maternal prednisolone excreted unchanged in breast milk was determined by (amount of prednisolone excreted in the breast milk over 1 dosing interval/maternal prednisone dose) × 100. Infant daily exposure to prednisone via breast milk was calculated by (amount of prednisone excreted in the breast milk over 1 dosing interval × number of prednisone doses per day)/(body weight of an age-matched 50th percentile infant girl according to the U.S. Centers for Disease Control growth chart). 8 The relative infant dose was calculated as (infant daily exposure/(maternal daily dose/maternal actual body weight) × 100.
One subject concurrently received cyclosporine, a substrate and competitive inhibitor of cytochrome P450 3A (CYP3A) and P-glycoprotein 9 during mid-(150 mg twice daily) and late (250 mg twice daily) pregnancy. Data regarding potential drug interactions between prednisolone and cyclosporine are conflicting. In a number of studies cyclosporine has been reported to decrease the clearance of prednisolone by 25% to 30%. [10] [11] [12] However, 3 smaller studies did not find an interaction between cyclosporine and prednisone and suggested that the drug interaction may depend on dosage, route of administration, disease course, or other factors. [13] [14] [15] Given that CYP3A accounts for only 18% of steroid metabolism, and this subject's PK parameters were all within the range of the other subjects, her PK was included in our analysis. No other subjects were taking medications known or suspected to interact with prednisone. Urine collection was incomplete for 3 subjects; therefore, their related PK parameters were not determined. Postpartum PK parameters were averaged for the subject who participated in both lactating and nonlactating study days.
Statistical Analyses
Statistical comparisons were made utilizing R 16 and the lme4 17, 18 package to complete linear mixed-effects analyses evaluating the relationship between dose and PK parameters of interest and the differences in prednisone and prednisolone PK between pregnancy and postpartum. The linear mixed-effect model analysis included all subjects (19 pregnant, 6 postpartum) and all doses (4-40 mg/day). In all cases we did not attempt to account for any direct interaction between variables other than the relationship in question, and only random intercepts were used so that the degrees of freedom could be held to an acceptable level. The method of maximum likelihood was used to fit the linear mixedeffect models. P-values (P ࣘ .05) were determined by analysis of variance (ANOVA); ie, comparing a null model without the effect under investigation to the model including it as a fixed effect. In all cases subject variability was included as a fixed effect to correct for repeated measures. No significant deviations from normality or homoscedasticity were noted by the Shapiro-Wilk test and visual inspection of Q-Q plots, histograms, and residual plots. One-way ANOVA was used to analyze prednisone and prednisolone PK during early, mid-, and late pregnancy to determine whether gestational age had a significant effect on total and unbound prednisone and prednisolone PK parameters. Results are reported as mean ± standard error plus the 95% confidence interval for linear mixed effect model analysis and mean ± standard deviation for all other analyses.
Results
Nineteen female subjects (9 black, 7 white, 1 Hispanicwhite, 1 Hispanic-unknown, and 1 Asian) participated in the study. Subjects participated in early-(n = 3), mid-(n = 9), and late-pregnancy (n = 14), postpartum with lactation (n = 2), and postpartum without lactation (n = 5) studies. One subject participated in both postpartum studies, ie, with and without lactation. Six subjects participated in both a pregnancy and a postpartum study. Among those 6 subjects, 2 subjects received the same dosage during pregnancy and postpartum. On study day 1, average age, height, and weight were 27 ± 6 years, 162 ± 11 cm, and 87 ± 21 kg, respectively. Prednisone indications included systemic lupus erythematosus (n = 11), rheumatoid arthritis (n = 3), asthma (n = 1), transplant recipient (n = 1), autoimmune hepatitis (n = 1), myasthenia gravis (n = 1), and Wegener granulomatosis (n = 1). Only 1 patient was also receiving a biologic agent (adalimumab).
Dose-Dependent PK Estimated total and unbound prednisone and prednisolone steady-state PK parameters during pregnancy in a subset of female subjects receiving 5, 10, or 20 mg of prednisone are summarized in Table 1 . All other dosage groups were limited to only 1 subject and were included in the linear mixed-effect model analysis but not included in the table. Total prednisone CL/F was dose dependent during pregnancy so that for every 1-mg increase in dose, prednisone CL/F increased by 0.7 ± 0.2 L/h (χ 2 = 10.8, P = .001, 95%CI [0.3, 1.0]). Prednisone Vβ/F was similarly dose dependent so that for every 1-mg increase in dose, Vβ/F increased by 3.1 ± 1.0 L (χ 2 = 7.5, P = .006, 95%CI [1.0, 5.2]). Prednisone AUC increased with dose, so that for every 1-mg increase in prednisone dose, prednisone AUC increased by 7.7 ± 1.0 ng•h/mL (χ 2 = 29.7, P < .001, 95%CI [5.6, 9.8]). Prednisone time to peak concentration increased with dose, so that for every 1-mg increase in prednisone dose, prednisone time to peak decreased by -0.01 ± 0.01 (χ 2 = 18.4, P < .001, 95%CI [-0.03, 0.01]). Prednisolone CL R likewise increased with dose, so that for every 1-mg increase in prednisone dose, prednisolone CL R increased by 0.02 ± 0.01 L/h (χ 2 = 9.6, P = .002, 95%CI [0.01, 0.04]). Prednisolone AUC increased with dose, so that for every 1-mg increase in prednisone dose, prednisolone AUC increased by 44.9 ± 9.5 ng•h/mL (χ 2 = 15.9, P < .001, 95%CI [24.8, 67.9] ). Similarly, urine prednisolone/prednisone metabolic ratios were altered by dose so that for every 1-mg increase in dose, urine metabolic ratio increased by 0.1 ± 0.0 (χ 2 = 5.5, P = .02, 95%CI [0.0, 0.1]). In contrast, prednisone half-life, peak concentration (C max ), CL R and percent of dose excreted unchanged in the urine as well as prednisolone half-life, C max , time to C max , CL/F, Vβ/F, and percentage of dose excreted in the urine did not exhibit significant dose dependency.
In addition to dose dependency of total prednisone PK, unbound prednisone CL/F also exhibited dose dependency during pregnancy so that for every 1-mg increase in dose, unbound prednisone CL/F increased 2.2 ± 0.9 L/h (χ 2 = 5.6, P = .02, 95%CI [0.4, 4.0]). Unbound prednisone AUC increased with dose, so that for every 1-mg increase in prednisone dose, prednisone AUC increased by 1.7 ± 0.2 ng•h/mL (χ 2 = 30, P < .001, 95%CI [1.2, 2.2]). Unbound prednisone C max increased with dose, so that for every 1-mg increase in prednisone dose, prednisone C max increased by 0.29 ± 0.04 ng/mL (χ 2 = 20.5, P < .001, 95%CI [0.20, 0.37]). In contrast, unbound prednisolone PK did not change with dose except for unbound prednisolone C max . For every 1-mg increase in prednisone dose, prednisolone C max increased by 1.7 ± 0.3 ng/mL (χ 2 = 21.2, P < .001, 95%CI [1.0, 2.4]).
Higher prednisone (r = 0.57, P ࣘ .05) and prednisolone (r = 0.75, P ࣘ .05) concentrations were associated with higher percentage unbound during pregnancy and postpartum. These data are consistent with concentration-dependent binding of prednisone and prednisolone within the therapeutic range (Figure 1) . Pregnancy was associated with significantly lower percentage unbound than postpartum for both prednisone ( Figure 1A , P = .003) and prednisolone AUC indicates area under the curve; CL/F, apparent oral clearance; CL R , renal clearance; C max , peak plasma concentration; MR, metabolic ratio; pln, prednisolone; pn, prednisone; t ½ , terminal half-life; T max , time to C max ; Vβ/F, apparent volume of distribution. a P value reflects significant differences across all pregnancy data controlled for subject and total daily dose utilizing the linear mixed-effects model analyses. b Reflects n = 4 for 5 mg, n = 5 for 10 mg, and n = 3 for 20 mg taking oral prednisone once daily. c Reflects n = 4 for 5 mg, n = 5 for 10 mg, and n = 6 for 20 mg due to incomplete urine collection in some subjects.
( Figure 1B , P < .001). Of note, there was a trend toward greater variability in the percentage unbound as the concentration of prednisolone increased above 200 ng/mL. Figure 2 depicts the steady-state, unbound plasma concentration-time profiles of a representative subject receiving prednisone 10 mg once daily during mid-pregnancy and 12 weeks postpartum. The concentration-time profiles look similar except for earlier peak concentrations of both prednisone and prednisolone during pregnancy. When pregnancy is compared to postpartum, including all subjects and all doses, prednisone and prednisolone PK parameters did not show significant differences except prednisolone CL/F. Prednisolone CL/F, in a subset of subjects receiving prednisone doses of 5, 10, and 20 mg, was 4.8 ± 0.3, 7.6 ± 3.3, and 9.4 ± 4.1 L/h during pregnancy, respectively, and 11.3, 7.6, and 11.6 ± 2.0 L/h postpartum, respectively. Only 1 subject was available as a comparator for postpartum prednisone doses 5 and 10 mg. When dose and intrasubject variability are controlled for, prednisolone CL/F was significantly lower during pregnancy compared to postpartum (χ 2 = 4.9, P = .03, 95%CI [-1.8, -0.1]).
PK of Prednisone and Prednisolone in Pregnancy Versus Postpartum
Gestational Age Effects. Total and unbound prednisone and prednisolone half-life, CL/F, and Vβ/F were similar across gestational ages (early, mid-, and late pregnancy), with no significant changes (data not shown). Figure 3 depicts a representative subject's steadystate prednisone and prednisolone concentration-time curves in breast milk and maternal plasma at 12 weeks postpartum. In the 2 subjects who participated in the lactation portion of the study, prednisolone concentrations in plasma were 22-fold and 14-fold higher than in breast milk at 3 hours postdose following 2 mg orally every 12 hours and 15 mg orally every 24 hours, respectively. In these same subjects, breast-milk/plasma AUC ratios were 0.5 and 0.6 for prednisone, and 0.02 and 0.03 for prednisolone, respectively. The relative infant doses as a percentage of the maternal body-weight-adjusted dose were 0.58% and 0.35% for prednisone and 0.18% and 0.09% for prednisolone. Prednisone and prednisolone were each below their limits of assay detection (4 ng/mL) in breast milk after 12 hours and 6 hours for these subjects, respectively. The unbound prednisone concentrations in the milk at 3 hours postdose were 2.4-to 3.8-fold higher than in maternal plasma. In contrast, unbound prednisolone concentrations were 1.3-to 1.5-fold lower in milk compared to maternal plasma.
Milk Concentrations
Cord Blood Concentrations
Venous and arterial umbilical cord and maternal plasma samples were collected from 13 subjects at delivery, 1.2 to 32 hours postdose. Most concentrations at the time of delivery were too low to be quantified. We were able to quantify maternal prednisolone to prednisone ratio in 5 subjects, umbilical cord venous prednisolone-to-prednisone ratio in 4 subjects, umbilical cord-to-maternal prednisolone ratio in 5 subjects, and umbilical cord-to-maternal prednisone ratio in 5 subjects. At the time of delivery, prednisolone-toprednisone concentration ratios were 15.1 ± 12.4 (range 4.1-32.2) and 0.5 ± 0.5 (range 0.2-1.3) in the mother and umbilical cord venous samples, respectively. Umbilical cord to maternal plasma concentration ratios were 0.2 ± 0.2 (range 0.1-0.6) and 4.0 ± 4.3 (range 0.8-11.4) for prednisolone and prednisone, respectively. Arterial to venous concentration ratios were measurable in 3 subjects for prednisolone and 2 subjects for prednisone. Umbilical cord arterial-to-venous plasma concentration ratios were 1.4 ± 0.5 and 0.9 ± 0.0 for prednisolone and prednisone, respectively. In addition, there was a strong correlation between maternal prednisolone concentrations and umbilical cord prednisone concentrations (r 2 = 0.97, data not shown).
Adverse Events and Outcomes
All reported adverse events related to the study days were minor and included bruising at venipuncture sites (n = 4), mild dizziness (n = 1), mild fatigue (n = 1), and hives from adhesive tape (n = 1). The hives resolved with diphenhydramine; the other events resolved without treatment. Labor and delivery information was available for 15 out of 19 subjects. Seven subjects delivered preterm, including 1 at 28 weeks, 1 at 34 weeks, 1 at 35 weeks, and 4 at 36 weeks of gestation. The rest of the subjects had unremarkable deliveries at term.
Discussion
We report, for the first time, the PK of oral prednisone and its active metabolite prednisolone during pregnancy. As described in the nonpregnant population, 5 prednisone also exhibits dose-dependent PK during pregnancy. Prednisone CL/F, unbound apparent oral clearance, and apparent oral volume of distribution increased significantly with increasing dose (Table 1 ). In addition, unbound fraction increased with increasing concentration. The increased fraction unbound in plasma is likely due to saturation of plasma protein binding at higher concentrations. This provides a partial explanation for the increased prednisone CL/F and apparent oral volume of distribution. The increase in prednisone unbound apparent oral clearance (P = .02) suggests additional changes as well, such as a decrease in bioavailability or increase in clearance with increasing dose. However, because prednisone is a lowextraction-ratio drug (<3%), 19 its bioavailability would not be expected to change with protein binding. The increased unbound prednisone apparent oral clearance with increased dose could either be explained by dosedependent increase in access to sites of metabolism or to a previously unrecognized dose-dependent intrinsic metabolic clearance process.
Although the prednisolone fraction unbound also increased with increasing prednisolone concentrations (Figure 1) , neither prednisolone CL/F nor unbound prednisolone CL/F exhibited statistically significant dose dependency in our subjects, but there was a trend toward increasing prednisolone total CL/F with increasing prednisone dose. In line with this trend, previous work in the nonpregnant population has reported increased total prednisolone clearance with higher doses. 5 That our data only showed a trend is likely a reflection of our small sample size. In addition, consistent with the previous study in nonpregnant subjects, 5 unbound prednisolone AUC and unbound prednisolone CL/F did not change with dose.
Given the physiological changes that occur over the course of pregnancy, we explored the effects of gestational age on total and unbound prednisone and prednisolone half-life, CL/F, and Vβ/F. Gestational age (early, mid-, and late pregnancy) did not significantly alter any of these PK parameters. Given our limited sample size, additional work is needed to confirm these findings.
Protein binding of prednisone and prednisolone is quite complex even in the nonpregnant population. Both prednisone and prednisolone are known to be highly bound to both albumin (low affinity, high capacity) and corticosteroid-binding globulin (high affinity, low capacity), both of which change during pregnancy. 6 Albumin concentrations are known to decrease by ß15%, and corticosteroid-binding globulin concentrations increase by 2-to 3-fold during normal pregnancy. The increase in corticosteroid-binding globulin concentrations during pregnancy increased the percentage bound of both prednisone and prednisolone as shown in Figure 1 (P = .003, P < .001, respectively). These results differ from those for most highly bound drugs, which are bound to albumin and α 1 -acid glycoprotein and have decreased plasma protein binding during pregnancy. The increased variability in percentage unbound for prednisolone concentrations above 200 ng/mL is likely explained by variability in corticosteroid-binding globulin 20 and albumin concentrations. In addition, binding of other endogenous competitors such as cortisol and cortisone might also affect saturation of binding sites.
Prednisone and prednisolone undergo interconversion. Type 1 11β-hydroxysteroid dehydrogenase (11β -HSD1) primarily converts prednisone to prednisolone in the liver. Outside the liver, in organs such as the placenta, kidney, and intestine, 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) primarily converts prednisolone to prednisone. 4 Pregnancy increases the CL/F of prednisolone. This could occur with either increased metabolism or decreased formation of prednisolone. Either increased 11β-HSD2 activity or decreased activity of 11β-HSD1 would increase prednisolone CL/F during pregnancy. Placental 11β-HSD2 appears to increase as pregnancy progresses, although further research on both enzyme activities is needed. 21, 22 Prednisolone is further metabolized by CYP3A, accounting for approximately 18% of its overall metabolism in the nonpregnant population.
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CYP3A activity is markedly increased during pregnancy, potentially contributing to the observed increase in prednisolone CL/F. 7 Another possible factor would be a decrease in protein binding, but this is unlikely because protein binding actually increased during pregnancy. The lack of change in the unbound prednisolone CL/F during pregnancy suggests that dose adjustments may not be needed based on the PK changes alone. However, this requires confirmation with a larger study. In addition, pharmacodynamic changes may or may not require dosage adjustment.
The relative concentrations of prednisone and prednisolone are highly dependent on 11β-HSD1 and 11β-HSD2 activities. At the time of delivery, 11β-HSD1 dominance would explain our observed prednisoloneto-prednisone ratio in maternal plasma of 15 ± 12 (range 4-32), slightly higher but consistent with previously reported values ranging from 3 to 9. 24, 25 However, in regard to umbilical cord concentrations, placental 11β-HSD2 activity appears more important. Both 11β-HSD1 and 11β-HSD2 are expressed in the placenta, but 11β-HSD2 activity is 7-to 8-fold higher than that of 11β-HSD1. 26 This differential activity is most likely responsible for the differing prednisoloneto-prednisone ratios in umbilical cord and maternal samples. We observed an umbilical cord plasma prednisolone-to-prednisone ratio of 0.5 ± 0.5 (range 0.2-1.3), consistent with previous reports (0.4 ± 0.2 and 0.5 ± 0.1). 24, 25 Differences in maternal and umbilical cord prednisolone-to-prednisone ratios might also be affected by differences in their placental P-glycoprotein affinity, although differences in transport efficiency in a stably transfected LLC-PK cell model are insufficient to explain our results. 27 Taken together, high relative expression and activity of 11β-HSD2 likely limit fetal exposure to the active prednisolone by backmetabolism to inactive prednisone.
Prednisolone umbilical cord venous-to-maternal plasma concentration ratio was 0.2 ± 0.2 (range 0.1-0.6) in our study, similar to previous reports (0.1 ± 0.0). 24, 25 In contrast, our prednisone umbilical cord venousto-maternal plasma concentration ratio was 4.0 ± 4.3 (range 0.8-11.4), which is higher and more variable than in previous reports (range 0.8-2.7). 24, 25 The high variability in the prednisone and prednisolone umbilical cord-to-maternal concentration ratios is potentially due to the high variability in placental 11β-HSD activity. The activities of 11β-HSD1 and 11β-HSD2 are dependent not only on differences in genetics but also on several external factors such as gestational age, preeclampsia, chorioamnionitis, and asthma. 21, 22, 28 This study had multiple subjects with preterm delivery that likely affected these ratios as well. The variability in dosing in our study likely contributed to the increased variability in prednisone umbilical cord to maternal concentration ratios.
Although the fetus does not contribute significantly to overall metabolic drug clearance by the maternalfetal unit during pregnancy, its ability to metabolize drugs can affect the local, fetal concentrations of drug and metabolites. 29 In the few subjects with quantifiable prednisone and prednisolone concentrations in both the umbilical arterial and venous plasma, the dominant fetal effect appeared to be conversion of prednisone to prednisolone, presumably by 11β-HSD1. With the drug passing through the fetus, this translated into umbilical cord arterial-to-venous concentration ratios of 1.4 ± 0.5 for prednisolone and 0.9 ± 0.0 for prednisone. This is consistent with previously published work reporting the presence of 11β-HSD1 near term in fetal organs. 30 Before mid-gestation, expression of 11β-HSD2 is dominant, and 11β-HSD1 has little to no expression in fetal tissues, 30 limiting exposure to active steroids until term. In a previous prospective study, glucocorticoid exposure during the first trimester of pregnancy (70% received prednisone) did not result in increased incidence of oral cleft or congenital anomalies. 31 However, 1 study found prednisone doses of >20 mg/day during pregnancy to be associated with an increased risk for cleft palate. 32 Evaluation of a doserelated effect would require further study. Interestingly, in a small controlled study, normal adrenal reserve was found in infants exposed in utero to long-term corticosteroid use. 33 Only 0.02% and 0.04% of the maternal prednisone dose was recovered in breast milk from each of 2 study participants. In a previous study, prednisone recovery in breast milk after a 2-hour collection was also very low (0.26% of the maternal dose). 34 The relative infant doses of prednisone (0.35 and 0.53%) and prednisolone (0.09 and 0.18%) appear clinically insignificant. Interestingly, unbound prednisone in breast milk at 3 hours postdose was 2.4-to 3.8-fold higher than the unbound prednisone in maternal plasma, whereas unbound prednisolone was 1.3-to 1.5-fold lower. Prednisone and prednisolone, both neutral and nonionizable drugs, are unlikely to be affected by the pH gradient between plasma and breast milk. Both are moderately lipophilic, low-molecular-weight compounds and are thus expected to readily cross the mammary epithelia. The slightly longer half-life of prednisone versus prednisolone (3.6 ± 0.4 hours and 2.2 ± 0.5 hours, respectively) is also an unlikely explanation for this difference. Both prednisone and prednisolone are substrates of the organic anion transporters. 35 However, whether transport of prednisone or prednisolone via organic anion transporters occurs in the mammary gland is not known. Although further research is required, this surprising concentration of unbound prednisone in breast milk may be explained by prednisolone backconversion mediated by mammary 11β-HSD2. This possibility is supported by elevated mammary 11β-HSD activity in the pregnant rat. 36 Short-term use of prednisone has been shown to be associated with maternal and fetal complications such as preterm delivery. 37 In addition, patients with autoimmune diseases or solid organ transplant recipients are at increased risk for preterm delivery and lowbirth-weight infants. [38] [39] [40] Consistent with these data, approximately half of the women participating in this study had preterm deliveries. The combination of prednisone and the patients' underlying medical conditions both may have contributed to the preterm deliveries observed in approximately half of our study subjects. It is not possible to differentiate the contributions by prednisone from those of the indications for its use in this relatively small study.
Conclusion
In conclusion, we report for the first-time detailed PK of prednisone and its active metabolite prednisolone during and after pregnancy. Prednisone exhibits dosedependent PK during pregnancy, but dose adjustment of prednisone may not be needed during pregnancy for PK reasons given the lack of change in unbound prednisolone apparent oral clearance. However, a larger sample size is needed to verify our results. In addition, gestational changes in prednisolone pharmacodynamics require further study and might affect dosage requirements. Both prednisone and prednisolone are found in breast milk in very low concentrations such that oral prednisone use appears compatible with breastfeeding.
